Status:
COMPLETED
Effect of Magnesium Supplementation in Selective Serotonin Reuptake Inhibitors Treated Major Depressive Disorder Patients
Lead Sponsor:
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Conditions:
MDD
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
A randomized, double-blind, placebo-controlled trial was conducted to assess the effect of magnesium glycinate on symptoms of moderate to severe depression in 90 patients. Patients were assessed at ba...
Detailed Description
Major depressive disorder (MDD), is a mood disorder affecting 300 million people worldwide with a prevalence of 6.7% in Bangladesh. Depression is the main contributor to suicidal deaths and is globall...
Eligibility Criteria
Inclusion
- Newly diagnosed 18 years or older MDD patients of both gender according to DSM-5 at the Outpatient Department of Psychiatry, BSMMU
- Moderate to severe MDD according to DASS-21 (scores of 14-27)
- Patients prescribed only SSRIs
Exclusion
- Patients having any other psychiatric disease, kidney disease, or gastrointestinal disease
- Taking dietary supplements in the last two months
- Taking fluoroquinolones, aminoglycosides, tetracyclines, calcium channel blockers, bisphosphonates, and skeletal muscle relaxants
- Pregnancy and lactation
Key Trial Info
Start Date :
March 18 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 21 2021
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04880460
Start Date
March 18 2021
End Date
November 21 2021
Last Update
March 21 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Basic Science and Paraclinical Science of BSMMU
Dhaka, Bangladesh